TD Cowen downgraded NGM Biopharmaceuticals to Market Perform from Outperform with a price target of $1.55, down from $4, after the company announced a merger agreement with affiliates of The Column Group, the company’s largest shareholder, for $1.55 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NGM:
- NGM Biopharmaceuticals Acquisition by Atlas Neon Parent
- NGM Biopharmaceuticals trading resumes
- NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
- NGM to be acquired by affiliates of The Column Group for $1.55 per share
- NGM Biopharmaceuticals trading halted, news pending
